Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and Lymphoma
Status:
Completed
Trial end date:
2020-07-28
Target enrollment:
Participant gender:
Summary
The main purpose of first-in-human IM156 study is to evaluate the safety and tolerability,
and to determine the maximum tolerated dose and recommended phase 2 dose of IM156.